Metastatic breast cancer

• Eli Lilly and Company

  Company7 trialsPhase 41,111 people

• Novartis Pharmaceuticals Corporation

  Company6 trialsPhase 41,210 people

• Pfizer

  Company3 trialsPhase 31,488 people

• Roche

  Company2 trialsPhase 31,613 people

• AbbVie

  Company2 trialsPhase 3807 people

• BriaCell Therapeutics Corporation

  Company2 trialsPhase 3440 people

• Daiichi Sankyo

  Company2 trialsPhase 3229 people

• DualityBio

  Company1 trialPhase 3541 people

National Cancer InstituteUS$2.4m

• Fit2ThriveMB: Optimization of a Physical Activity Promotion Intervention for Metastatic Breast Cancer Patients

  National Cancer InstituteNorthwestern UniversityUS$664k2026–2031

• Every Day Counts: A lifestyle program for women metastatic breast cancer

  National Cancer InstituteMedical College of WisconsinUS$644.1k2022–2027

• Improving CAR-T cell therapy in metastatic breast cancers by reprogramming obesity-aggravated tumor microenvironment via physical activity

  National Cancer InstituteMassachusetts General HospitalUS$416.8k2025–2027

• Phase 1a/1b Trial of Exercise Treatment in Hormone Receptor-Positive Metastatic Breast Cancer

  National Cancer InstituteSloan-kettering Inst Can ResearchUS$657.8k2019–2024